Concepts (228)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 25 | 2023 | 106 | 6.730 |
Why?
|
| Prostate | 13 | 2022 | 33 | 3.800 |
Why?
|
| Kidney Neoplasms | 13 | 2023 | 60 | 3.080 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2023 | 35 | 2.160 |
Why?
|
| Image-Guided Biopsy | 11 | 2022 | 26 | 1.840 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 1221 | 1.490 |
Why?
|
| Robotic Surgical Procedures | 4 | 2023 | 18 | 1.300 |
Why?
|
| Robotics | 3 | 2023 | 10 | 1.190 |
Why?
|
| Nephrectomy | 8 | 2017 | 29 | 1.010 |
Why?
|
| Nomograms | 1 | 2021 | 5 | 0.840 |
Why?
|
| Germ-Line Mutation | 3 | 2016 | 9 | 0.820 |
Why?
|
| Male | 43 | 2023 | 15621 | 0.760 |
Why?
|
| Humans | 52 | 2023 | 29337 | 0.670 |
Why?
|
| Waiting Lists | 1 | 2017 | 15 | 0.630 |
Why?
|
| Kidney Transplantation | 3 | 2017 | 125 | 0.610 |
Why?
|
| Renal Dialysis | 1 | 2017 | 113 | 0.580 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 3 | 0.580 |
Why?
|
| Retrospective Studies | 13 | 2023 | 3273 | 0.570 |
Why?
|
| Ultrasonography, Interventional | 6 | 2020 | 63 | 0.550 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 16 | 0.550 |
Why?
|
| Heterozygote | 1 | 2016 | 103 | 0.550 |
Why?
|
| Laparoscopy | 4 | 2023 | 145 | 0.510 |
Why?
|
| Ultrasonography | 6 | 2019 | 226 | 0.500 |
Why?
|
| Biopsy | 6 | 2022 | 234 | 0.490 |
Why?
|
| Middle Aged | 28 | 2022 | 9823 | 0.470 |
Why?
|
| Aged | 21 | 2022 | 9448 | 0.460 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 5 | 2020 | 8 | 0.430 |
Why?
|
| Perineum | 2 | 2021 | 5 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2017 | 26 | 0.420 |
Why?
|
| Biopsy, Large-Core Needle | 3 | 2021 | 6 | 0.370 |
Why?
|
| Kidney Diseases | 2 | 2012 | 115 | 0.370 |
Why?
|
| Prostatic Hyperplasia | 3 | 2013 | 17 | 0.350 |
Why?
|
| Ureter | 2 | 2023 | 15 | 0.330 |
Why?
|
| Multimodal Imaging | 3 | 2017 | 20 | 0.300 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 32 | 0.290 |
Why?
|
| Prospective Studies | 6 | 2023 | 1811 | 0.290 |
Why?
|
| Kidney | 3 | 2023 | 173 | 0.280 |
Why?
|
| Adult | 14 | 2017 | 8601 | 0.240 |
Why?
|
| Ureteral Obstruction | 1 | 2023 | 11 | 0.240 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 4851 | 0.230 |
Why?
|
| Combined Modality Therapy | 2 | 2023 | 364 | 0.230 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2022 | 1 | 0.220 |
Why?
|
| Cystectomy | 2 | 2019 | 4 | 0.210 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2021 | 36 | 0.210 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 4 | 0.210 |
Why?
|
| Prostatectomy | 2 | 2023 | 18 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 4 | 2004 | 18 | 0.190 |
Why?
|
| Urinary Bladder | 1 | 2019 | 20 | 0.180 |
Why?
|
| Urology | 1 | 2019 | 16 | 0.180 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 521 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2019 | 32 | 0.180 |
Why?
|
| Survival Rate | 2 | 2017 | 349 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 402 | 0.170 |
Why?
|
| Ablation Techniques | 1 | 2017 | 3 | 0.160 |
Why?
|
| United States | 4 | 2017 | 2333 | 0.160 |
Why?
|
| Female | 14 | 2017 | 16197 | 0.160 |
Why?
|
| Transplant Recipients | 1 | 2017 | 22 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 32 | 0.150 |
Why?
|
| DNA Mutational Analysis | 2 | 2015 | 56 | 0.150 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2017 | 3 | 0.150 |
Why?
|
| Phototherapy | 1 | 2017 | 37 | 0.150 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 20 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2017 | 62 | 0.150 |
Why?
|
| ErbB Receptors | 1 | 2017 | 72 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 43 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 5 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 188 | 0.140 |
Why?
|
| Herpesvirus 4, Human | 3 | 2004 | 13 | 0.140 |
Why?
|
| Succinate Dehydrogenase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2015 | 2 | 0.130 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 3 | 0.130 |
Why?
|
| Disease Management | 2 | 2016 | 114 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 161 | 0.130 |
Why?
|
| Neoplasm Grading | 4 | 2018 | 45 | 0.130 |
Why?
|
| Kallikreins | 1 | 2014 | 2 | 0.130 |
Why?
|
| Prognosis | 5 | 2017 | 840 | 0.120 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2013 | 3 | 0.120 |
Why?
|
| SEER Program | 4 | 2015 | 38 | 0.120 |
Why?
|
| Animals | 5 | 2017 | 4552 | 0.120 |
Why?
|
| Genetic Testing | 1 | 2013 | 64 | 0.120 |
Why?
|
| Urothelium | 1 | 2013 | 5 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2013 | 4 | 0.120 |
Why?
|
| Estrogens | 1 | 2013 | 33 | 0.120 |
Why?
|
| Time Factors | 1 | 2017 | 1616 | 0.110 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2002 | 19 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 324 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 90 | 0.100 |
Why?
|
| Fungal Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Threonine | 1 | 2011 | 7 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 7 | 0.100 |
Why?
|
| Molecular Chaperones | 1 | 2011 | 12 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 1830 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2023 | 3478 | 0.090 |
Why?
|
| Survival Analysis | 3 | 2016 | 298 | 0.090 |
Why?
|
| Watchful Waiting | 2 | 2022 | 7 | 0.090 |
Why?
|
| Nitriles | 2 | 2022 | 13 | 0.080 |
Why?
|
| Young Adult | 4 | 2015 | 1932 | 0.080 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 264 | 0.080 |
Why?
|
| Malacoplakia | 1 | 2006 | 1 | 0.070 |
Why?
|
| Pyelonephritis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Tuberculosis, Renal | 1 | 2006 | 1 | 0.070 |
Why?
|
| Emphysema | 1 | 2006 | 4 | 0.070 |
Why?
|
| Adolescent | 4 | 2015 | 2279 | 0.070 |
Why?
|
| Abscess | 1 | 2006 | 26 | 0.070 |
Why?
|
| Risk Factors | 3 | 2022 | 2443 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 389 | 0.070 |
Why?
|
| Depsipeptides | 1 | 2004 | 1 | 0.060 |
Why?
|
| Burkitt Lymphoma | 1 | 2004 | 7 | 0.060 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2004 | 9 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 13 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 12 | 0.060 |
Why?
|
| Child | 3 | 2015 | 1346 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 145 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 7 | 0.060 |
Why?
|
| Kidney Pelvis | 1 | 2023 | 9 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2014 | 1939 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2003 | 10 | 0.060 |
Why?
|
| Organ Size | 2 | 2013 | 107 | 0.060 |
Why?
|
| Incidence | 2 | 2017 | 756 | 0.060 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 1 | 0.060 |
Why?
|
| Benzamides | 1 | 2022 | 16 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 218 | 0.050 |
Why?
|
| Canada | 1 | 2022 | 56 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2017 | 679 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2013 | 101 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2017 | 24 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 124 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2001 | 22 | 0.050 |
Why?
|
| Phenylurea Compounds | 1 | 2021 | 1 | 0.050 |
Why?
|
| Androgens | 1 | 2021 | 8 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2001 | 66 | 0.050 |
Why?
|
| Patient Selection | 2 | 2013 | 232 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 340 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 170 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 1607 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 553 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 788 | 0.050 |
Why?
|
| Education | 1 | 2019 | 39 | 0.040 |
Why?
|
| Simulation Training | 1 | 2019 | 34 | 0.040 |
Why?
|
| HIV Infections | 1 | 2006 | 970 | 0.040 |
Why?
|
| Infrared Rays | 1 | 2017 | 1 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2017 | 5 | 0.040 |
Why?
|
| Immunoconjugates | 1 | 2017 | 10 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 260 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 2015 | 1 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 29 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2002 | 957 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 94 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 87 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 4 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 290 | 0.030 |
Why?
|
| Heredity | 1 | 2013 | 6 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2014 | 57 | 0.030 |
Why?
|
| Dutasteride | 1 | 2013 | 2 | 0.030 |
Why?
|
| Azasteroids | 1 | 2013 | 2 | 0.030 |
Why?
|
| Finasteride | 1 | 2013 | 3 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 330 | 0.030 |
Why?
|
| Pedigree | 1 | 2013 | 77 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2013 | 24 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 35 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2013 | 20 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 3 | 0.030 |
Why?
|
| Age of Onset | 1 | 2013 | 108 | 0.030 |
Why?
|
| Contrast Media | 1 | 2014 | 125 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 2 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 30 | 0.030 |
Why?
|
| Propionates | 1 | 2013 | 12 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 23 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 20 | 0.030 |
Why?
|
| Michigan | 1 | 2013 | 16 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 18 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2013 | 30 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 81 | 0.030 |
Why?
|
| Nephrons | 1 | 2012 | 6 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 81 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 222 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 175 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 355 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 79 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2013 | 201 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2012 | 24 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 68 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 184 | 0.030 |
Why?
|
| Solvents | 1 | 2011 | 5 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2011 | 53 | 0.030 |
Why?
|
| Comorbidity | 1 | 2013 | 498 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 340 | 0.030 |
Why?
|
| Chaperonins | 1 | 2011 | 1 | 0.030 |
Why?
|
| Casein Kinase II | 1 | 2011 | 2 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 441 | 0.030 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2011 | 9 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 19 | 0.030 |
Why?
|
| Disease Progression | 1 | 2014 | 787 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 130 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 18 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 29 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 17 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2011 | 61 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2011 | 159 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 482 | 0.020 |
Why?
|
| Chicago | 1 | 2013 | 865 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2004 | 724 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 843 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 959 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 402 | 0.020 |
Why?
|
| Caspase Inhibitors | 1 | 2004 | 4 | 0.020 |
Why?
|
| Thymidine | 1 | 2004 | 7 | 0.020 |
Why?
|
| Viral Matrix Proteins | 1 | 2004 | 4 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 28 | 0.020 |
Why?
|
| Cell Division | 1 | 2004 | 113 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 45 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2004 | 198 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2004 | 107 | 0.020 |
Why?
|
| Thymidine Kinase | 1 | 2003 | 2 | 0.010 |
Why?
|
| Zidovudine | 1 | 2003 | 39 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2003 | 26 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 251 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2003 | 174 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 323 | 0.010 |
Why?
|
| Leukocyte Transfusion | 1 | 2001 | 2 | 0.010 |
Why?
|
| Mice, SCID | 1 | 2001 | 55 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2003 | 132 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 65 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 277 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2001 | 86 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 91 | 0.010 |
Why?
|
| Rats | 1 | 2003 | 854 | 0.010 |
Why?
|